die('
Site is under construction
Dear site users
Site is under construction.
The site will be ready in less than 24 hours.
We are sorry for the inconvenience.
www.yektaweb.com
');
Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61882/rbmb
en
jalali
1401
8
1
gregorian
2022
11
1
11
3
online
1
fulltext
en
Evaluation of The Effect of Letrozole in the Ovarian Hyperstimulation Syndrome Prevention in Participants at Risk of Treatment with Ovulation-Stimulating Drugs: A Randomized Controlled Trial
بیوشیمی
Biochemistry
مقالات اصلی
Original Article
<div style="text-align: justify;"><span style="font-size:12pt"><span style="font-family:TimesNewRomanPS-BoldItalicMT"><span style="color:#000000"><span style="font-weight:bold"><span style="font-style:italic">Background: </span></span></span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">This study aims to evaluate the effect of Letrozole (LE) in reducing ovarian </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">hyperstimulation syndrome (OHSS) in high-risk participants with polycystic ovary syndrome (PCOS) </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">treated with </span></span></span><span style="font-size:12pt"><span style="font-family:TimesNewRomanPS-ItalicMT"><span style="color:#000000"><span style="font-style:italic">In vitro </span></span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">fertilization (IVF).</span></span></span><br>
</div>
<div style="text-align: justify;"><span style="font-size:12pt"><span style="font-family:TimesNewRomanPS-BoldItalicMT"><span style="color:#000000"><span style="font-weight:bold"><span style="font-style:italic">Methods: </span></span></span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">This study was a randomized clinical trial in which participants were randomly divided </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">into two groups (n= 25 per group). Based on GnRH-antagonist protocol, recombinant follicle </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">stimulating hormone 150 units/day subcutaneously and human menopausal gonadotropin 75 units/</span></span></span><span new="" roman="" style="color: rgb(0, 0, 0); font-family: " times="">day intramuscularly used from day 2 of the menstrual cycle. In the study group, Letrozole 5 mg daily </span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">was added simultaneously with gonadotropin during the first five days of the IVF cycle and in the </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">control group placebo was added.</span></span></span><br>
</div>
<div style="text-align: justify;"><span style="font-size:12pt"><span style="font-family:TimesNewRomanPS-BoldItalicMT"><span style="color:#000000"><span style="font-weight:bold"><span style="font-style:italic">Results: </span></span></span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">There were statistically significant differences among the groups in terms of Estradiol level </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">on Trigger Day (p= 0.04). The total days of stimulation and cumulative Gonadotropin dose were </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">significantly lower in the Letrozole group (p= 0.00). There were no significant differences between </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">the groups in terms of the number of oocytes retrieved, numbers of implanted embryos, and clinical </span></span></span></div>
<div style="text-align: justify;"><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">pregnancy rates (p-value> 0.05). There was only one moderate case in the intervention group and 9 </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">moderate symptoms in the control group (p= 0.04).</span></span></span><br>
</div>
<div style="text-align: justify;"><span style="font-size:12pt"><span style="font-family:TimesNewRomanPS-BoldItalicMT"><span style="color:#000000"><span style="font-weight:bold"><span style="font-style:italic">Conclusions:</span></span></span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">Administration of Letrozole with GnRH antagonist protocol, conventional protocol in </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">PCOS cases in IVF cycle, had a significant effect on reducing the incidence of OHSS. So, if the future </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">studies prove LE co-administration may lessen the incidence of OHSS, LE will be a highly potent </span></span></span><span style="font-size:12pt"><span style="font-family:Times New Roman"><span style="color:#000000">drug for preventing OHSS in PCOS cases.</span></span></span></div>
In vitro fertilization, Infertility, Letrozole, Ovarian hyperstimulation syndrome.
386
393
http://rbmb.net/browse.php?a_code=A-10-995-1&slc_lang=en&sid=1
Hatav
Ghasemi Tehrani
100319475328460013367
100319475328460013367
No
Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Keihaneh
Aasasi
100319475328460013368
100319475328460013368
No
Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Farahnaz
Mardanian
100319475328460013369
100319475328460013369
No
Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Ferdous
Mehrabian
100319475328460013370
100319475328460013370
No
Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Minoo
Movahedi
100319475328460013371
100319475328460013371
No
Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Elham
Naghshineh
Naghshineh@med.mui.ac.ir
100319475328460013372
100319475328460013372
Yes
Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.